During Friday’s Morning trade, Shares of Valero Energy Corporation (NYSE:VLO), lost -1.81% to $70.39.
Valero Energy Corporation, declared that it will host a conference call on January 28, 2016 at 11:00 a.m. ET to discuss fourth quarter earnings results, which will be released earlier that day, and provide an update on company operations.
Valero Energy Corporation operates as an independent petroleum refining and marketing company in the United States, Canada, the Caribbean, the United Kingdom, and Ireland. It operates through two segments, Refining and Ethanol. The Refining segment is involved in refining, wholesale marketing, product supply and distribution, and transportation operations.
Shares of Host Hotels and Resorts Inc (NYSE:HST), declined -2.22% to $15.40, during its current trading session.
Host Hotels & Resorts, Inc. (HST) declared that its board of directors authorized a regular quarterly cash dividend of $0.20 per share on the Company’s common stock representing an annual dividend yield of over 5%, based on yesterday’s closing stock price. The dividend is payable on January 15, 2016, to stockholders of record on December 31, 2015.
Host Hotels & Resorts, Inc. is a publicly owned real estate investment trust (REIT). The firm primarily engages in the ownership and operation of hotel properties. It invests in the real estate markets of United States. It also invests in Canada, Mexico, Chile, the United Kingdom, Italy, Spain, and Poland.
Finally, Horizon Pharma PLC (NASDAQ:HZNP), gained 0.94%, and is now trading at $21.48.
Horizon Pharma plc, declared that it will present at the 34th Annual J.P. Morgan Healthcare Conference. Timothy P. Walbert, chairman, president and chief executive officer, will present at 11:30 a.m. Pacific Time (1:30 p.m. Central Time) on January 13, 2016. Mr. Walbert will review the company’s financials, provide details regarding its orphan, primary care and rheumatology business units and business development strategy.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.